Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Diane FrankelIsabelle Nanni-MetellusAndrée Robaglia-SchluppPascale TomasiniJulien GuindeFabrice BarlesiPhilippe AstoulL'Houcine OuafikFlorent AmatoreVéronique SecqElise KaspiPatrice RollPublished in: Clinical chemistry and laboratory medicine (2019)
When cancer cells are present in the CSF, the molecular profiling from the cell pellets is relevant, as it can detect supplemental or different mutations compared to a previous analysis of the primitive tumour or plasma cell-free DNA and allows the adaptation of the treatment strategy.